These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 22954609)

  • 1. Allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS): how can we improve outcomes in the near future?
    Phillips GL
    Leuk Res; 2012 Dec; 36(12):1490-5. PubMed ID: 22954609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Lee HC; Saliba RM; Rondon G; Chen J; Charafeddine Y; Medeiros LJ; Alatrash G; Andersson BS; Popat U; Kebriaei P; Ciurea S; Oran B; Shpall E; Champlin R
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1948-54. PubMed ID: 26183077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mini-transplant for acute myeloblastic leukemia and myelodysplastic syndrome].
    Kanda Y
    Nihon Rinsho; 2003 Sep; 61(9):1565-72. PubMed ID: 14515725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.
    Krishnamurthy P; Potter VT; Barber LD; Kulasekararaj AG; Lim ZY; Pearce RM; de Lavallade H; Kenyon M; Ireland RM; Marsh JC; Devereux S; Pagliuca A; Mufti GJ
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):562-8. PubMed ID: 23266740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
    Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
    Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome.
    de Lima M; Giralt S
    Semin Hematol; 2006 Apr; 43(2):107-17. PubMed ID: 16616044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-unit cord blood transplantation after granulocyte colony-stimulating factor-combined myeloablative conditioning for myeloid malignancies not in remission.
    Konuma T; Kato S; Ooi J; Oiwa-Monna M; Ebihara Y; Mochizuki S; Yuji K; Ohno N; Kawamata T; Jo N; Yokoyama K; Uchimaru K; Asano S; Tojo A; Takahashi S
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):396-401. PubMed ID: 24333750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up.
    Shimoni A; Hardan I; Shem-Tov N; Yerushalmi R; Nagler A
    Leukemia; 2010 May; 24(5):1050-2. PubMed ID: 20147978
    [No Abstract]   [Full Text] [Related]  

  • 11. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.
    Valcárcel D; Martino R
    Curr Opin Oncol; 2007 Nov; 19(6):660-6. PubMed ID: 17906468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation.
    Oran B; Giralt S; Couriel D; Hosing C; Shpall EJ; de Meis E; Khouri IF; Qazilbash M; Anderlini P; Kebriaei P; Popat U; Carrasco-Yalan A; Champlin RE; de Lima M
    Leukemia; 2007 Dec; 21(12):2540-4. PubMed ID: 17611563
    [No Abstract]   [Full Text] [Related]  

  • 13. Is there a role for autologous stem cell transplantation for patients with acute myelogenous leukemia? A retrospective analysis.
    Novitzky N; Thomas V; du Toit C; McDonald A
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):875-84. PubMed ID: 20870030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion.
    Eefting M; de Wreede LC; Halkes CJ; von dem Borne PA; Kersting S; Marijt EW; Veelken H; Putter H; Schetelig J; Falkenburg JH
    Haematologica; 2016 Apr; 101(4):506-14. PubMed ID: 26802054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.
    Craddock CF
    Bone Marrow Transplant; 2008 Mar; 41(5):415-23. PubMed ID: 18209726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transplant for MDS: challenges and emerging strategies.
    Tamari R; Castro-Malaspina H
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):43-54. PubMed ID: 25659729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need.
    Shimoni A; Nagler A
    Best Pract Res Clin Haematol; 2011 Sep; 24(3):369-79. PubMed ID: 21925090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.
    Hamaki T; Kami M; Kim SW; Onishi Y; Kishi Y; Murashige N; Hori A; Kojima R; Sakiyama M; Imataki O; Heike Y; Tanosaki R; Masuo S; Miyakoshi S; Taniguchi S; Tobinai K; Takaue Y
    Bone Marrow Transplant; 2004 May; 33(9):891-900. PubMed ID: 15048142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors for patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing myeloablative or non-myeloablative allogeneic blood stem cell transplantation.
    Graef T; Vaupel M; Fenk R; Ruf L; Zohren F; Germing U; Haas R; Kobbe G
    Hematol Oncol; 2007 Dec; 25(4):170-7. PubMed ID: 17579887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.